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Abstract We hypothesised that L-carnitine could accel-
erate recovery from exhaustive exercise since increased
blood L-carnitine concentrations elicit a vasodilation in
isolated animal vessels as well as in patients with
peripheral vascular or coronary artery disease during
exercise. Twelve subjects received either 2 g L-carnitine
or a placebo in a study which was double-blind and
crossover in design. Two hours after administration, the
subjects performed a constant-load exercise test (CET1)
cycling at their individual anaerobic threshold to
exhaustion. Three hours later this test was repeated
(CET2). After 4–14 days, each subject performed the
same cycling tests after having taken the other sub-
stance. Exercise times of the 12 subjects were identical
with L-carnitine (CET1: 21.3±5.7 min; CET2:
21.4±5.3 min) and placebo (CET1: 21.9±6.2 min;
CET2: 20.4±4.8 min). Also, heart rate, oxygen con-
sumption, respiratory exchange ratio, and blood lactate
concentration were identical. In conclusion, 2 g of L-
carnitine taken 2 h before a ﬁrst of two constant-load
exercise tests had no inﬂuence on the second tests per-
formed 3 h after the ﬁrst test compared with placebo.
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Introduction
It is still a matter of debate whether the administration
of L-carnitine improves performance of intensive
endurance exercise (Brass 2000). Most scientiﬁc studies
rather question a positive eﬀect of L-carnitine on a single
exercise bout. The lack of an eﬀect of L-carnitine on
exercise performance is not surprising taking into con-
sideration that oral L-carnitine administration increases
blood L-carnitine concentration (e.g., Rizza et al. 1992)
but does not aﬀect the L-carnitine content of skeletal
muscles (Wa¨chter et al. 2002).
Besides an inﬂuence on a single exercise bout, L-car-
nitine administration might improve recovery from exer-
cise (Karlic and Lohninger 2004; Volek et al. 2002). Better
recovery from exhaustive exercise should improve the
outcome of the next exercise bout performed on the same
or on the following day. Besides its enhancing fat-burning
eﬀect, an increased blood L-carnitine concentration can
elicit a vasodilation as shown by the following facts: the
endothelium of isolated rat heart vessels normally loses its
ability to regulate blood ﬂow under hypoxic and ischemic
conditions with the result that cellular damage occurs
(Dauber et al. 1990; Hu¨lsmann and Dubelaar 1992; Tsao
and Lefer 1990). When L-carnitine is added, ability of the
endothelial cells to regulate blood ﬂow in ischaemia is
prolonged and the occurrence of cellular damage is
postponed (Hu¨lsmann and Dubelaar 1992). In another
study, L-carnitine enhanced the eﬀects of vasodilators in
isolated bovine arteries (Bettini et al. 1990). A vasoactive
eﬀect of L-carnitine is also evident in clinical studies: In
patients with peripheral vascular disease, L-carnitine
administration enhances the hyperemic response after
ischaemia (Brevetti et al. 1989) and increases the walking
distance (Brevetti et al. 1988; Signorelli et al. 2001). In
patients with coronary artery disease, L-carnitine intake
increases the coronary blood ﬂow during exercise (Fu-
jiwara et al. 1991) and prolongs exercise duration before
ischaemicECGchanges occur (Bartels et al. 1996;Cherchi
et al. 1985; Lagioia et al. 1992). These eﬀects are evident
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during exercise but absent at rest (Brevetti et al. 1989;
Fujiwara et al. 1991). In addition, Giamberardino et al.
(1996) found that L-carnitine exerts a protective eﬀect
against pain and damage from eccentric eﬀort. Taken
together, L-carnitine seems to improve the endothelial
cells’ ability to maintain an adequate blood ﬂow during
hypoxia or exercise.
Thus, we asked whether this vasodilative eﬀect of L-
carnitine might improve peripheral circulation in healthy
subjects also. This eﬀect could occur either towards the
end of exhaustive constant-load endurance exercise,
which is rather unlikely from what we discussed before,
or during recovery from exhaustive exercise. A positive
recovery eﬀect of L-carnitine should improve a sub-
sequent constant-load endurance exercise test. So far,
only one study (Colombani et al. 1996) has investigated
subsequent exercise with and without L-carnitine.
Twenty-four hours after a marathon run no diﬀerence
was found between the incremental test to exhaustion
with or without L-carnitine. As a recovery time of 24 h
is rather long and constant-load exercise is more
appropriate than incremental exercise concerning pos-
sible vasodilatory eﬀects, we investigated two exhaustive
constant-load exercise tests in a randomised, double-
blind study with and without the administration of L-
carnitine on the same day. We found no positive
recovery eﬀect of L-carnitine in well-trained subjects.
Materials and methods
Subjects
Twelve healthy, well-trained men, age 25±3 years
(mean±SD), body mass 71±6 kg, height 178±3 cm
participated in the study. Procedures were in accordance
with the Helsinki Declaration of 1975 and subjects were
informed in detail about the protocols before they gave
their written informed consent. Subjects were advised to
continue their habitual training and to abstain from
exhaustive training three days prior to testing. They
noted every training in a diary, which was regularly
controlled during the study.
Equipment
Cycling tests were performed on an electromagnetically
braked cycle Ergometrics 900 (Ergoline, Bitz, Germany).
Ventilation and gas exchange were measured with an
OxyconGamma unit (Jaeger, Hoechberg, Germany)
using a turbine for ventilation measurement, a para-
magnetic analyser for O2 determination, and an infrared
absorption analyser for CO2 measurement. Five-second
averages of heart rate (HR) were recorded with a heart
rate monitor (Polar, Kempele, Finland). Blood lactate
concentration was determined from samples of ear lobe
capillary blood using an enzymatic method (ESAT 6661,
Eppendorf, Hamburg, Germany).
Protocols
First, the following preliminary test was performed:
maximal power output (Wmax), peak oxygen uptake
_V
O2,peak
 
; and the ventilatory anaerobic threshold
(ATV) were determined with an incremental exercise test.
The initial workload was 100 W. Every 2 min, the load
was increased by 30 W until subjects were exhausted.
Subjects were free to choose their personal favourite
pedalling frequency within 60–100 min1. Once estab-
lished, pedalling frequency had to be maintained
throughout the cycling tests, i.e., during the incremental
as well as during the constant-load exercise tests (see
below). In all cycling tests, exhaustion was assumed ei-
ther when subjects stopped cycling or when the pedalling
frequency fell below 90% of the individually chosen
frequency for more than 5 s despite a strong request of
an investigator to increase the frequency.
After 4–7 days, subjects started with the main tests of
the study consisting of two constant-load cycling
endurance tests (CET, i.e., CET1 and CET2) on one day,
and the same two CETs on another day 4–14 days later.
CET1 was performed in the morning, CET2 followed
after 3 h of rest. Two hours before each CET1, subjects
took an indistinguishable tablet (double-blinded) con-
taining either 2 g L-carnitine or a placebo. The order of
the L-carnitine or placebo administration was rando-
mised. All CETs followed the same standardised pro-
tocol: the subjects started with 100 W for 5 min before
the workload was set to the individual ATV determined
during the preliminary incremental exercise test. The
subjects exercised with the individually determined
workload until they were exhausted. Mean ATV
amounted to 294±52 W (84±5% Wmax) with a _VO2
of 58±8 ml kg1 min1 91 7% _V
O2,peak
 
: Subjects
were allowed to monitor their pedalling frequency but
were not given any additional information or encour-
agement. Heart rate and ventilatory parameters were
measured continuously throughout the cycling test.
Blood samples were taken every 2 min during the ﬁrst
10 min of cycling, thereafter every 3 min, and at
exhaustion in order to determine lactate concentration.
Between CET1 and CET2 subjects drank Isostar (Wan-
der, Berne, Switzerland), a sports drink with carbohy-
drates. The provided 0.9 g kg1 h1 carbohydrates led
to a high glycogen resynthesis rate (vanHall et al. 1998).
Other food intake was not allowed.
Calculations and statistical analysis
Before the order of L-carnitine and placebo adminis-
tration was disclosed, inspection of raw data by analysis
of variance (ANOVA) with repeated measures revealed
that cycling times, HR, _VO2 ; R, lactate concentration,
and subjective impression of performance were statisti-
cally not diﬀerent between days 1 and 2. Therefore, we
do not present these results.
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After the disclosure of the substance order, the
eﬀects of L-carnitine were compared with the eﬀects of
placebo using ANOVA with repeated measures.
Cycling times, HR, _VO2 ; R, and lactate concentration
are presented as mean±SD. Since the shortest CET
lasted 15 min, HR, _VO2 ; R, and lactate concentration
were compared during two separate periods: (1)
0–15 min after the beginning of cycling and (2) the
last 6 min before the end of the cycling endurance
tests. Because of missing values due to technical
problems, the number of subjects included in each
analysis varies (exact numbers are given in Fig. 1).
Results are presented as mean±SD. Signiﬁcance was
accepted if P<0.05.
Fig.1 Heart rate, blood lactate
concentration, respiratory
exchange ratio, and oxygen
uptake are plotted during
cycling at 100 W (0–5 min after
start) and at the anaerobic
threshold (5–15 min after the
start as well as the last 6 min
before the end of cycling) in a
constant-load exercise test
(CET). No statistically
signiﬁcant diﬀerences at equal
exercise times were found
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Results
Preliminary testing
Subjects achieved a _V
O2,peak of 64±9 ml kg
1 min1,
aWmax of 346±52 W, a HRmax of 185±6 beats min
1,
and a maximal lactate concentration of 11.7±3.6 mmol
l1 in the incremental exercise test.
CET results
Averaged cycling times of the CETs were similar: after
L-carnitine administration, the 12 subjects exercised
21.3±5.7 min in CET1 and 21.4±5.3 min in CET2
(P=0.888), respectively. After placebo administration,
they exercised 21.9±6.2 min in CET1 and 20.4±4.8 min
in CET2 (P=0.167), respectively. Cycling time diﬀer-
ences (CET2 minus CET1) were similar (P=0.152)
after L-carnitine (+0.1±2.2 min) and placebo (1.5±
3.5 min). Lactate concentration of CET1 showed a trend
towards higher concentrations compared to lactate
concentration of CET2 irrespective of L-carnitine or
placebo administration (Fig. 1; P=0.056). HR
(P=0.111), _VO2 (P=0.986), and R (P=0.194) were
similar.
Discussion
Two grams of L-carnitine improved neither CET1 nor
CET2 compared to placebo in 12 well-trained male
subjects. The similar CET1 cycling times after L-carni-
tine and placebo administration conﬁrmed that L-car-
nitine had no eﬀect on a single performance as found in
previous studies (Brass 2000). In addition, our new ap-
proach of repeating the intensive constant-load exercise
bout within 3 h elicited no advantage of L-carnitine
compared to placebo. _VO2 ; R, lactate concentration, and
the subjective impression of performance were also not
diﬀerent between L-carnitine and placebo administra-
tion. Therefore, we speculate that 2 g of L-carnitine 2 h
prior to CET1 or about 5 h prior to CET2 did not have a
vasodilative eﬀect important enough to improve exercise
performance in either of these tests. Also, the lack of an
improvement of CET2 disproved an eﬀect of L-carnitine
during recovery in well-trained subjects.
One might wonder if a higher oral dose than 2 g of
L-carnitine would alter the outcome of our study. This
is not likely since the mucosal absorption of L-carni-
tine is saturated by a 2g dose (Harper et al. 1988).
Furthermore, the 2g dose causes maximal blood L-
carnitine for as long as 6 h (Lagioia et al. 1992).
Therefore, it is unlikely that repetitive oral dosing at
short intervals would lead to higher blood L-carnitine
concentrations. In addition, we cannot exclude that a
shorter interval between the two CETs in well-trained
subjects or the same protocol in untrained subjects
might give a diﬀerent result.
In conclusion, 2 g of L-carnitine taken 2 h before a
ﬁrst of two constant-load exercise tests had no inﬂuence
on the second tests performed 3 h after the ﬁrst test
compared with placebo.
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